Table 5.

Probability of success (expressed as CFR or cumulative fraction of response) of tedizolid and linezolid for staphylococci.

Microorganism/Study	Resistance Phenotype	Probability of Success (CFR, %)
		Tedizolid	Linezolid
S. aureus
Sahm et al. [22]		99	69
Zurenko et al. [23]		99	67
Rodríguez-Avial et al. [24]	LR	97	3
Pfaller et al. [25]		100	n.c.
MRSA
Sahm et al. [22]			71
Barber et al. [26]	hVISA	99	n.c.
	VISA	100	n.c.
	DNS	100	n.c.
	LR	80	n.c.
Peñuelas et al. [27]	MRSA	99	75
	MLRSA	62	n.c.
Pfaller et al. [25]		100	n.c.
CoNS
Sahm et al. [22]		94	n.c.
Zurenko [23]		99	93
Rodríguez-Avial et al. [24]	LR	20	0
Pfaller et al. [25]		100	n.c.

DNS: daptomycin-non-susceptible; LR: linezolid resistant; hVISA: heterogenous vancomycin intermediate; VISA: vancomycin intermediate; MRSA: methicillin-resistant S. aureus, MLRSA: methicillin- and linezolid-resistant S. aureus. n.c.: not calculated due to lack of MIC data.